慢性丁型肝炎的治疗新进展

肝脏 ›› 2022, Vol. 27 ›› Issue (3): 264-266.

慢性丁型肝炎的治疗新进展

王岩, 李涛, 王磊

250033 青岛山东大学第二医院感染及肝病科

收稿日期:2022-02-14 出版日期:2022-03-31 发布日期:2022-05-31

Received:2022-02-14 Online:2022-03-31 Published:2022-05-31

摘要/Abstract

摘要： 全球2%~15%的乙型肝炎病毒(HBV)感染者合并感染丁型肝炎病毒(HDV)。通常来讲,慢性HBV/HDV合并感染者更易进展为肝硬化、肝衰竭以及肝细胞癌等不良结局。过去30年,聚乙二醇化干扰素-α已被用于经验性治疗慢性HDV感染,但其停药后的病毒学应答率只有约20%。近年来,3种新型抗HDV化合物,包括HBsAg分泌抑制剂(核酸多聚体REP2139)、戊烯化抑制剂(法尼醇蛋白转移酶抑制剂LNF)和进入肝细胞抑制剂Bulevirtide(BLV,原例MyrcludexB),已先后进行了Ⅱ期和Ⅲ期临床试验。本文拟针对HDV的治疗终点和治疗新靶点进行总结。

关键词: HDV, HBsAg分泌抑制剂, 戊烯化抑制剂, 入肝细胞抑制剂, 治疗终点

王岩, 李涛, 王磊. 慢性丁型肝炎的治疗新进展[J]. 肝脏, 2022, 27(3): 264-266.

参考文献

[1] Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol,2020,73:523-532.
[2] Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol,2021,74:1200-1211.
[3] Wranke A, Hardtkes, Heidrich B, et al. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. J Viral Hepat,2020,27:1359-1368.
[4] Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol,2019,70:1008e15.
[5] European Association for the Study of the Liver. EASL 2017 clinical practiceguidelines on the management of hepatitis virus infection. J Hepatol,2017,67:370-398.
[6] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology,2018,67:1560-1599.
[7] Castelnau C, LeGal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta:relevance of quantitative RT-PCR for follow-up. Hepatology,2006,44:728-735.
[8] Wedemeyer H, Yurdaydìn C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med,2011,364:322-331.
[9] Wedemeyer H, Yurdaydin C, Hardtke S, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D(HIDIT-II):a randomised,placebo controlled, phase 2 trial. Lancet Infect Dis,2019,19:275-286.
[10] Al-Mahtab M, Bazinet M, Vaillant A. Safety and Efficacy of Nucleic Acid Polymersin Monotherapy and Combined with Immunotherapy in Treatment-Naïve Bangladeshi Patients with HBeAg+Chronic Hepatitis B Infection. PLoS One,2016,11:e0156667.
[11] Bazinet M, Pantea V, Cebotarescu V, et al. Safety and efficacy of REP2139 and pegylatedinterferon alfa-2a for treatment-na?ve patients with chronic hepatitis virus and hepatitis Dvirusco-infection(REP301 and REP301-LTF): an on-randomised, open label, phase 2 trial. Lancet Gastroenterol Hepatol,2017,2:877-889.
[12] Bazinet M, Pântea V, Cebotarescu V,et al. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis Virus/Hepatitis Delta Virus Coinfection. Hepatol Commun,2020,5:189-202.
[13] Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnibin chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2 Atrial. Lancet Infect Dis,2015,15:1167-1174
[14] Yurdaydin C, Keskin O, Kalkan C, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWRHDV-1 study. Hepatology,2018,67:1224-1236.
[15] Yurdaydin C, Idilman R, Keskin O, et al. Aphase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWRHDV-2 study. J Hepatol,2017,66:S33-34.
[16] Koh C, Surana P, Han MAT, et al. Aphase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis-end of study results from the LOWRHDV-3 study. JHepatol,2017,66:S101-S102.
[17] Wedemeyer H, Port K, Deterding K, et al. Aphase 2 dose-escalation study of lonafarnib plus ritonavirin patients with chronic hepatitis D: final results from the lonafarnib with ritonavirin HDV-4(LOWRHDV-4)study. J Hepatol,2017,66:S24.
[18] Etzion O, Hamid SS, Lurie Y, et al. End of study results from LIMTHDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambdamono therapy in patients with chronic hepatitis delta virus infection. JHepatol,2019,70(suppl):e32
[19] Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. JVirol,2005,79:1613-1622.
[20] Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol,2018,68(suppl):S3.
[21] Wedemeyer H, Schoeneweis K, Bogomolov PO, et al. Final results of a multicenter, open-label phase2 clinical trial(MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon Alpha2a in patients with chronic HBV/HDV co-infection. J Hepatol,2019,70:E81.